NCT01872182

Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 20 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to evaluate efficacy and safety of ALS-L1023 tablet in patients with abdominal obesity of metabolic syndrome.

Conditions

• Abdominal Obesity Metabolic Syndrome

Interventions

Type	Name	Description
DRUG	ALS-L1023	daily twice for 12 weeks
DRUG	placebo	daily twice for 12 weeks

Timeline

• Start date: 2013-05-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2013-06-07
• Last updated: 2016-10-11

Locations

1 site across 1 country: South Korea